Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 13/20 | 0.75 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.62 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.62 |
| ▸ | TMIGD3 | P0DMS9 | 7/20 | 0.58 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.58 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.58 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.57 |
| ▸ | HTR2C | P28335 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20122089 | 0.90 | ADORA3 (0.76) | ADORA3SLC6A2SLC6A3KCNH2TMIGD3 | |
| SCHEMBL21939411 | 0.88 | ADORA3 (0.75) | ADORA3SLC6A2SLC6A3KCNH2TMIGD3 | |
| SCHEMBL22359744 | 0.86 | ADORA3 (0.76) | ADORA3SLC6A2SLC6A3KCNH2TMIGD3 | |
| SCHEMBL16774291 | 0.86 | ADORA3 (1.00) | ADORA3SLC6A2SLC6A3KCNH2TMIGD3 | |
| SCHEMBL16774154 | 0.86 | ADORA3 (1.00) | ADORA3SLC6A2SLC6A3KCNH2TMIGD3 | |
| SCHEMBL20122127 | 0.86 | ADORA3 (1.00) | ADORA3SLC6A2SLC6A3KCNH2TMIGD3 | |
| SCHEMBL23097551 | 0.85 | ADORA3 (0.77) | ADORA3SLC6A2SLC6A3KCNH2TMIGD3 | |
| SCHEMBL20122119 | 0.84 | ADORA3 (0.61) | ADORA3TMIGD3ADORA1 | |
| SCHEMBL20122091 | 0.83 | ADORA3 (1.00) | ADORA3SLC6A2SLC6A3KCNH2TMIGD3 | |
| SCHEMBL16774299 | 0.83 | ADORA3 (1.00) | ADORA3SLC6A2SLC6A3KCNH2TMIGD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220117985-A1 | TREATMENT OF CHRONIC HEADACHES | UNIVERSITY OF MARYLAND, BALTIMORE | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220117985-A1 | TREATMENT OF CHRONIC HEADACHES | ADORA3, ADORA2B, ADORA2A | ADORA3 1/4885SLC6A2 386/4885SLC6A3 298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.